Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.

Kinon BJ, Kollack-Walker S, Stauffer V, Liu-Seifert H.

J Clin Psychopharmacol. 2012 Jun;32(3):420-2. doi: 10.1097/JCP.0b013e3182549d10. No abstract available.

PMID:
22561475
2.

Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.

Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A.

Am J Psychiatry. 2011 Sep;168(9):957-67. doi: 10.1176/appi.ajp.2011.10060907. Epub 2011 Jun 15.

PMID:
21676992
3.

The influence of personality traits and beliefs about medicines on adherence to asthma treatment.

Emilsson M, Berndtsson I, Lötvall J, Millqvist E, Lundgren J, Johansson A, Brink E.

Prim Care Respir J. 2011 Jun;20(2):141-7. doi: 10.4104/pcrj.2011.00005.

4.

The heterogeneity of antipsychotic response in the treatment of schizophrenia.

Case M, Stauffer VL, Ascher-Svanum H, Conley R, Kapur S, Kane JM, Kollack-Walker S, Jacob J, Kinon BJ.

Psychol Med. 2011 Jun;41(6):1291-300. doi: 10.1017/S0033291710001893. Epub 2010 Oct 7.

5.

Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.

Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J.

J Clin Psychopharmacol. 2008 Dec;28(6):601-7. doi: 10.1097/JCP.0b013e31818aaf6c.

PMID:
19011427
6.

Extrapyramidal side-effects of antipsychotics in a randomised trial.

Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

Br J Psychiatry. 2008 Oct;193(4):279-88. doi: 10.1192/bjp.bp.108.050088.

7.

EPS profiles: the atypical antipsychotics are not all the same.

Weiden PJ.

J Psychiatr Pract. 2007 Jan;13(1):13-24. Review.

PMID:
17242588
8.

Premorbid functioning and treatment response in recent-onset schizophrenia.

Rabinowitz J, Harvey PD, Eerdekens M, Davidson M.

Br J Psychiatry. 2006 Jul;189:31-5.

9.

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.

Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R.

Value Health. 2006 Mar-Apr;9(2):77-89.

10.

Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies.

Tunis SL, Johnstone BM, Kinon BJ, Barber BL, Browne RA.

Value Health. 2000 May-Jun;3(3):232-42. Review.

11.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

12.
13.

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Correll CU, Leucht S, Kane JM.

Am J Psychiatry. 2004 Mar;161(3):414-25. Review.

PMID:
14992963
16.

Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients.

Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP.

Am J Psychiatry. 1999 Feb;156(2):309-11.

PMID:
9989570
17.

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.

Am J Psychiatry. 1997 Apr;154(4):457-65.

PMID:
9090331
18.

Should clinical trials with concurrent economic analyses be blinded?

Freemantle N, Drummond M.

JAMA. 1997 Jan 1;277(1):63-4. No abstract available.

PMID:
8980212
19.

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.

Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S.

Psychopharmacology (Berl). 1996 Mar;124(1-2):159-67.

PMID:
8935812
20.

Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.

Glazer WM, Morgenstern H, Doucette JT.

J Clin Psychiatry. 1993 Apr;54(4):133-9.

PMID:
8098030

Supplemental Content

Support Center